House Proposes Bill to Eliminate Extra Patents in Healthcare

Why It Matters

A June 4 House Judiciary subcommittee hearing on pharmaceutical patents put a spotlight on a practice that generic drug manufacturers say is quietly keeping drug prices elevated long after brand-name exclusivity was supposed to expire. At the center of the debate: the ETHIC Act — short for Eliminating Thickets to Increase Competition Act — and a statement for the record from Dr. Rachel Goode, Senior Vice President and Head of Legal and Intellectual Property at Fresenius Kabi, a leading generic IV drug manufacturer.

The central tension is straightforward: brand-name pharmaceutical companies are filing clusters of overlapping patents on a single drug, layering protection well beyond the original patent's expiration. Generic manufacturers say this blocks competition. Brand-name companies say patents protect innovation. Congress is now weighing whether the law needs to intervene.

The Big Picture

The Hatch-Waxman Act of 1984 was designed to strike a balance — reward pharmaceutical innovation with a period of exclusivity, then open the door to generic competition to bring prices down. The ETHIC Act hearing was built around the argument that brand-name manufacturers have found ways to game that system.

Rather than relying solely on the original patent covering a drug's core molecule, companies now file additional patents covering formulations, manufacturing processes, delivery methods, and minor variations. The result is a thicket of patents that generic manufacturers must navigate — or litigate around — before they can bring a competing product to market.

The bill's core mechanism targets this directly: it would limit brand-name drug companies to asserting only one patent per duplicative patent cluster in litigation against a generic manufacturer. The goal is to prevent companies from using patent volume as a litigation weapon to delay competition.

Adding urgency to the proceedings was a recent Supreme Court ruling in the Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. case, which reshaped the legal landscape around pharmaceutical patents and gave the legislative debate fresh relevance.

Political Stakes

For the Administration

The Trump administration has made lowering prescription drug prices a stated priority, pursuing executive actions including Most Favored Nation pricing policies. The ETHIC Act represents a legislative complement to those efforts — addressing the supply side of the drug pricing problem by removing barriers to generic competition, rather than imposing price controls on the demand side.

But there is a tension. The administration has also sought to strengthen domestic pharmaceutical manufacturing and has courted the brand-name pharma sector for investment and development partnerships. The ETHIC Act directly challenges brand-name industry interests, and passage could complicate those relationships.

For Congress

The bill's sponsorship is notably bipartisan. House co-sponsors include Republicans and Democrats alike, a relative rarity on pharmaceutical policy, where industry lobbying tends to fracture coalitions along less predictable lines. A Senate companion bill, S. 2276, has also been introduced in the 119th Congress.

That bipartisan support gives Republican leadership a potential vehicle for a drug pricing win that doesn't rely on price controls — a policy approach that has historically been more palatable to the GOP. For Democrats, the bill aligns with longstanding messaging around pharmaceutical accountability and consumer costs.

The political risk for both parties lies in the opposition. Brand-name pharmaceutical manufacturers are among the most active lobbying forces in Washington, and any legislation perceived as undermining patent protections will draw sustained resistance.

For the Public

Generic drugs account for the large majority of prescriptions filled in the United States, and IV generics are a staple of hospital care. When patent thickets delay those drugs from reaching the market, the costs are borne by patients, insurers, and health systems. The ETHIC Act hearing put that dynamic on the record in a formal congressional setting, with a senior industry executive from the generic side making the case directly to lawmakers.

The Bottom Line

The ETHIC Act represents a concrete legislative challenge to a pharmaceutical industry practice that generic manufacturers say undermines the competitive framework Congress established in 1984. The bill has bipartisan backing and addresses a drug pricing concern that both the current administration and members of both parties have claimed as a priority.

Whether that alignment translates into legislative momentum is the open question. The Hikma Supreme Court ruling has shifted the legal terrain, and the hearing record now includes a direct industry argument for reform. The gap between a well-attended hearing and a floor vote, however, remains the most consequential distance in Washington.

Spot something wrong? Report an issue with this article